​Capitalize on the Future of Medical Imaging with PreDx
Age-related diseases are one of the largest and fastest-growing healthcare markets in the world.
Yet today, senescent cells can only be measured by biopsy or post-mortem analysis. PreDx changes that.
Our bio-responsive MRI agents quantify senescent cells in real time, in living tissue — enabling a new era of drug development and precision diagnostics.
​
Massive Opportunity in Two Lead Indications
We are laser-focused on two of the largest unmet-need diseases where senescence drives progression and where a real-time biomarker is urgently needed:
Osteoarthritis (OA)
-
~32.5 million U.S. patients today
-
No cure, limited ability to measure disease biology
-
Senescence burden is a major driver of cartilage degradation
​
Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD/NAFLD)
-
Up to 100 million U.S. adults affected
-
Many progressing silently toward liver fibrosis and cancer
-
Senescence plays a central role in disease worsening
​
Together, these two diseases alone represent a U.S. market exceeding $5.8 billion in annual imaging potential — with far larger demand globally as healthcare access expands.
By enabling real-time, non-invasive monitoring of senescent cells in osteoarthritic joints, our technology promises to revolutionize the way osteoarthritis is studied and managed. As we advance, we anticipate our bio-responsive MR contrast agents being used as companion diagnostics, paving the way for safer and more effective osteoarthritis treatments.
​
By reducing the number of animals required for testing and shortening trial periods, our technology promises to revolutionize the way gene therapy trials are performed. As we move into the future, we anticipate our bio-responsive MR contrast agents being used as companion diagnostics, paving the way for safer and more effective gene therapy treatments.
With a firm belief in the vast potential of our technology and a commitment to advancing its application in both gene therapy and osteoarthritis, PreDx invites you to become a part of our groundbreaking journey. By investing in our cutting-edge technology, you are contributing to the transformation of the gene therapy and osteoarthritis markets, making an impact on countless lives that could benefit from these therapies. Get in touch with us today to learn more about the potential returns and how you can contribute to the evolution of healthcare. Together, we can shape the future of medicine.
​
​